← back to search

Inge Tinhofer

German Cancer Research Center · DE
Area of research
Otorhinolaryngology · Cancer Research
Research interest
Research interests include Head and Neck Cancer Studies, Cancer, Hypoxia, and Metabolism, Chronic Lymphocytic Leukemia Research, and Radiomics and Machine Learning in Medical Imaging.
h-index
31
citations
3,128
works
106
NIH funding
primary concept
email

Recent publications

Multitask Learning with Convolutional Neural Networks and Vision Transformers Can Improve Outcome Prediction for Head and Neck Cancer Patients
Cancers 2023cited by 8position: middledoi
The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts
Radiotherapy and Oncology 2023cited by 1position: middledoi
Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy
Radiotherapy and Oncology 2022cited by 6position: middledoi
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT
Cancers 2022cited by 5position: middledoi
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
European Journal of Cancer 2021cited by 54position: middledoi
2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma
Scientific Reports 2020cited by 58position: middledoi
Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC
Cancers 2020cited by 30position: middledoi
Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma
Clinical and Translational Radiation Oncology 2020cited by 18position: middledoi
DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.
Journal of Clinical Oncology 2020cited by 5position: middledoi
Clinical impact of comprehensive versus targeted genomic analysis for precision oncology.
Journal of Clinical Oncology 2019cited by 0position: middledoi
Precision oncology for the treatment of salivary gland tumors.
Journal of Clinical Oncology 2019cited by 0position: middledoi
Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy
Clinical Cancer Research 2018cited by 54position: middledoi
BEST OF: A phase III study assessing the best of radiotherapy (Intensity Modulated RadioTherapy, IMRT) compared to the best of surgery (Trans-Oral Surgery, TOS) in patients with T1-T2, N0 oropharyngeal squamous cell carcinoma (OPSCC).
Journal of Clinical Oncology 2018cited by 4position: middledoi
Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Journal of Clinical Oncology 2018cited by 3position: middledoi
Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Journal of Clinical Oncology 2018cited by 2position: firstdoi
EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—"UPSTREAM".
Journal of Clinical Oncology 2018cited by 2position: middledoi
Efficacy of a structured workflow for the interpretation of comprehensive genomic analysis data in clinical routine.
Journal of Clinical Oncology 2018cited by 1position: middledoi
A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling
Scientific Reports 2017cited by 226position: middledoi
The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
International Journal of Cancer 2017cited by 98position: middledoi
Heat shock protein 70 and tumor‐infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK‐ROG)
International Journal of Cancer 2017cited by 63position: middledoi
SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy
Radiotherapy and Oncology 2017cited by 32position: middledoi
Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC
Radiotherapy and Oncology 2017cited by 22position: middledoi
SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy
Clinical and Translational Radiation Oncology 2017cited by 20position: middledoi
Association of an APOBEC mutational signature, mutational load, and BRCAness with inflammation and PD-L1 expression in HNSCC.
Journal of Clinical Oncology 2017cited by 3position: middledoi
Comprehensive targeted next-generation sequencing to reveal limited clonal evolution after concurrent chemoradiation in patients with squamous cell carcinoma of the head and neck.
Journal of Clinical Oncology 2017cited by 1position: firstdoi
HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Radiotherapy and Oncology 2016cited by 138position: middledoi
Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Clinical Cancer Research 2016cited by 131position: middledoi
Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix
Oncotarget 2016cited by 39position: middledoi
Standard or split TPF induction chemotherapy followed by bioradiation: ICRAT randomized phase II study.
Journal of Clinical Oncology 2016cited by 4position: middledoi
Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas.
Journal of Clinical Oncology 2016cited by 1position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Volker Budach · Freie Universität Berlin13 papers (2014–2020)Panagiotis Balermpas · University of Zurich13 papers (2014–2023)Daniel Zips · Auguste-Viktoria-Klinik12 papers (2014–2023)Mechthild Krause · German Cancer Research Center12 papers (2014–2023)Stephanie E. Combs · Brooke Army Medical Center12 papers (2014–2023)Claus Belka · Cancer Research Center12 papers (2014–2023)Ulrich Keilholz · German Marine Research Consortium12 papers (2015–2020)Annett Linge · German Cancer Research Center12 papers (2014–2023)Michaël Baumann · European CanCer Organisation12 papers (2014–2023)Fabian Lohaus · German Cancer Research Center10 papers (2014–2023)Damian Rieke · German Cancer Research Center8 papers (2016–2019)Martin Stuschke · German Cancer Research Center8 papers (2014–2018)Claus Rödel · Goethe University Frankfurt7 papers (2014–2018)Sebastian Ochsenreither · Deutschen Konsortium für Translationale Krebsforschung7 papers (2016–2019)Steffi Pigorsch · Technical University of Munich7 papers (2014–2018)Ute Ganswindt · Innsbruck Medical University7 papers (2017–2023)Frederick Klauschen · Institute of Clinical Cancer Research7 papers (2016–2019)Steffen Löck · German Cancer Research Center7 papers (2014–2023)Amir Abdollahi · German Cancer Research Center7 papers (2014–2018)Jürgen Debus · NYU Langone Health7 papers (2014–2018)